Check-Cap (NASDAQ:CHEK) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Check-Cap (NASDAQ:CHEK) in a research report sent to investors on Sunday. The brokerage issued a sell rating on the medical research company’s stock.

Check-Cap Stock Performance

Shares of CHEK opened at $1.28 on Friday. The business’s 50-day moving average is $1.00 and its two-hundred day moving average is $1.47. The company has a market capitalization of $7.49 million, a P/E ratio of -0.43 and a beta of 0.17. Check-Cap has a fifty-two week low of $0.56 and a fifty-two week high of $3.45.

About Check-Cap

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation.